Clinical Trial Detail

NCT ID NCT03911453
Title Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Arizona
Indications

triple-receptor negative breast cancer

Therapies

Rucaparib

Age Groups: adult senior

No variant requirements are available.